ALY688, a synthetic adiponectin receptor agonist peptide, delivered during ischemia or at reperfusion and daily for 28 days, significantly improved ejection fraction and fractional shortening, reduced infarct size, and lowered cardiac troponin-I in a rat myocardial ischemia-reperfusion model. The mechanism operates on two fronts: in the myocardium, ALY688 activates macrophages to secrete TGFβ1, which drives naïve CD4+ T cells toward regulatory T cell (Treg) differentiation, suppressing IL-1β/IL-23/IL-6 inflammasome signaling. Simultaneously, it activates RORγt/IL-17 signaling in the intestine to upregulate tight junction proteins Claudin-1 and ZO-1, reducing systemic LPS translocation. Multi-omics confirmed attenuation of pathogenic gut metabolites including anthranilic acid and imidazole propionate post-infarction.
This finding is genuinely noteworthy because it frames post-MI cardiac damage as a gut-heart immunometabolic circuit — an underexplored but increasingly credible framework. The dual-compartment mechanism, simultaneously resolving cardiac inflammation and fortifying intestinal barrier integrity, distinguishes ALY688 from conventional cardioprotective approaches. Adiponectin signaling has long been associated with cardiometabolic protection, but peptide agonists like ALY688 offer receptor-targeted specificity without the pharmacokinetic complexities of the full protein. Critical limitations apply: this is a rat model only, with no human pharmacokinetic or safety data. The 28-day dosing window raises translational questions about clinical timing post-MI. The Treg/Th17 balance manipulation also carries immunosuppression risks. Still, the mechanistic granularity here — linking macrophage polarization, gut metabolomics, and cardiac proteomics — makes this an incrementally paradigm-shifting preclinical contribution warranting accelerated human-stage investigation.
